文献速递放疗物理与技术

2018至2019年磁共振成像引导直线加速器早期应用的国家模式

National Patterns of Early Adoption of Magnetic Resonance Imaging-Guided Linear Accelerators in 2018 to 2019.
PubMed 文献 · Adv Radiat Oncol · 2023-01-09

该研究利用美国国家癌症数据库评估2018至2019年自适应磁共振成像引导直线加速器(aMRI-LINAC)的早期应用情况。2018至2019年仅171例患者接受aMRI-LINAC治疗,最常见治疗部位为肺、胰腺、前列腺和乳腺。与匹配的IMRT患者相比,aMRI-LINAC治疗的患者在肺癌或乳腺癌中更可能于综合癌症中心或学术中心接受治疗。

要点

  • 2018至2019年NCDB仅记录171例患者接受aMRI-LINAC治疗,可能被低估。
  • aMRI-LINAC最常见治疗部位为肺(33例)、胰腺(30例)、前列腺(29例)和乳腺(23例)。
  • 肺癌或乳腺癌患者接受aMRI-LINAC治疗更可能位于综合癌症中心或学术中心。

核心结论

  • aMRI-LINAC在FDA批准后NCDB记录的应用可能被低估、进展缓慢,且集中于学术实践中心。
  • 需要进一步纵向研究评估实践模式随更广泛应用如何演变。

研究设计与样本

  • 利用国家癌症数据库(NCDB)评估2018至2019年aMRI-LINAC早期应用,汇总43个疾病部位。
  • 从2018至2019年接受IMRT的患者中按分期对前4大癌症部位进行1:1匹配。
  • 比较aMRI-LINAC组与匹配IMRT组的9项特征(年龄、白人比例、都市区居住比例、最高收入四分位比例、Medicare保险比例、无保险或保险状态未知比例、综合癌症中心或学术中心治疗比例、无记录Charlson-Deyo合并症比例、最高教育程度地区居住比例)。

主要发现

  • 2018至2019年NCDB仅记录171例患者接受aMRI-LINAC治疗,其中56%为男性,89%为白人,54%参加Medicare。
  • aMRI-LINAC最常见治疗部位为肺(33例)、胰腺(30例)、前列腺(29例)和乳腺(23例)。
  • aMRI-LINAC组与匹配IMRT组在9项特征上无显著差异,但肺癌或乳腺癌患者接受aMRI-LINAC治疗显著更可能在综合癌症中心或学术中心接受治疗。

局限性

  • aMRI-LINAC在NCDB中的记录可能被低估。
  • 需要进一步纵向研究评估实践模式随更广泛应用如何演变。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Adaptive magnetic resonance imaging-guided linear accelerators (aMRI-LINACs) are an emerging technology with the potential to improve radiation treatment for cancer through improved visualization and adaptive treatment. Given the competing forces of the increased cost, knowledge, and staff required for aMRI-LINAC therapy, it is unpredictable how rapidly and for whom aMRI-LINAC therapy is being adopted. Therefore, given that aMRI-LINAC therapy was granted approval from the Food and Drug Administration in late 2017, we evaluated the National Cancer Database (NCDB) to obtain a nationwide view of early aMRI-LINAC adoption in 2018 to 2019. METHODS AND MATERIALS: Forty-three disease sites were aggregated. A sample of patients who underwent intensity modulated radiation therapy (IMRT) from 2018 to 2019 were matched 1:1 by stage for the top 4 cancer sites. We then compared 9 characteristics of interest (age, % White [vs non-White], % residing in metro areas, % living in the greatest income quartile, % insured by Medicare, % uninsured or unknown insurance status, % treated at a comprehensive cancer center or academic center, % with no recorded Charlson-Deyo comorbidities, and % residing in an area with highest educational) between the 2 samples (aMRI-LINAC and matched IMRT). RESULTS: Only 171 patients were recorded as having been treated with aMRI-LINACs in the NCDB in 2018 to 2019. Fifty-six percent were male, 89% White, and 54% enrolled in Medicare. The most common sites of disease treated were lung (33 patients), pancreas (30 patients), prostate (29 patients), and breast (23 patients). There were no significant differences between aMRI-LINAC- and IMRT-matched patients except that patients with lung or breast cancer treated with aMRI-LINAC were significantly more likely to be treated at a comprehensive cancer center or academic center. CONCLUSIONS: aMRI-LINAC adoption recorded in the NCDB after Food and Drug Administration approval was potentially underreported, slow, and attributed to academic sites of practice. Further longitudinal study will be needed to assess how practice patterns evolve with greater adoption.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Yu JB, Kinslow CJ, Cheng SK, et al. National Patterns of Early Adoption of Magnetic Resonance Imaging-Guided Linear Accelerators in 2018 to 2019. Adv Radiat Oncol. 2023. PMID: 36798607. doi:10.1016/j.adro.2022.101167

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。